目的 探讨半枝莲-白花蛇舌草药对的物质基础及药理作用机制。方法 利用中药系统药理分析平台（TCMSP）中提取出半枝莲和白花蛇舌草的化学成分，以口服利用度（OB）≥30%、类药性（DL）≥0.18为条件筛选出候选化合物，并通过该数据库检索与活性成分相关的作用靶点以及与靶点相关的疾病；利用CTD在线分析平台查询靶点相关的主要生物学通路。从而构建出成分-靶点、靶点-疾病、靶点-生物学通路网络图。结果 通过筛选，得到33个候选化合物，相应靶点230个，相关疾病319种。其中度值较高的候选成分为槲皮素、木犀草素等；候选化合物作用的核心靶点为PTGS1、PTGS2及HSP90等；潜在靶标与肿瘤、神经退行性疾病、精神性疾病、心血管疾病、炎症性疾病等319种疾病相关联；靶点相关的主要生物学通路有肿瘤、免疫系统相关，以及钙信号通路等30条。结论 本研究对半枝莲-白花蛇舌草药对的物质基础及作用机制进行初步探讨，为进一步深入研究其药理作用机制提供参考。
Objective To investigate the components and pharmacology mechanism of Scutellaria Barbata-Hedyotis diffusa pair by network pharmacology. Method All of chemical components related to the two traditional Chinese medicines were collected from the TCMSP database, the oral bioavailability (OB) ≥ 30% and drug likeness(DL) ≥ 0.18 were used as the screeing conditions for candidate compounds. The targets and diseases related to molecular compounds were found through the TCMSP, the biological pathways related to targets were found through CTD online analysis platform. Result The 33 candidateactive molecules, 230 corresponding targets and 319 related diseases were obtained through network pharmacology screning. The components with higher degree value included quercetin and luteolin. The top three targets were PTGS1, PTGS2 and HSP90, these targets can joint in 30 pathways, such as pathways in cancer、immune system, calcium signaling. And these compounds may play a role in cancer, cardiovascular disease, inflammatory diseases. Conclusion The results preliminarily verify the activity components and pharmacology mechanism of Scutellaria Barbata-Hedyotis diffusa Pair, and provides a good foundation for further study on the mechanism of action.